Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 17/20 | 0.72 |
| ▸ | CDK1 | P06493 | 8/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.59 |
| ▸ | CDK4 | P11802 | 2/20 | 0.58 |
| ▸ | CDKL1 | Q00532 | 1/20 | 0.58 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.51 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.51 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.51 |
| ▸ | CCND1 | P24385 | 1/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.51 |
| ▸ | CCND3 | P30281 | 1/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.51 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.51 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.51 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.51 |
| ▸ | GSK3A | P49840 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | CDK7 | P50613 | 1/20 | 0.51 |
| ▸ | CDK9 | P50750 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1447419 | 0.91 | CDK2 (0.61) | CDK2CDK1KCNH2CDK4CDKL1 | |
| SCHEMBL1447533 | 0.90 | CDK2 (0.82) | CDK2CDK1KCNH2CDK4CDKL1 | |
| SCHEMBL1448435 | 0.89 | CDK2 (0.57) | CDK2CDK1KCNH2CDK4CDKL1 | |
| SCHEMBL1447609 | 0.88 | CDK2 (0.75) | CDK2CDK1KCNH2CDK4CDKL1 | |
| SCHEMBL1447605 | 0.88 | CDK2 (0.75) | CDK2CDK1KCNH2CDK4CDKL1 | |
| SCHEMBL1447825 | 0.87 | CDK2 (0.77) | CDK2CDK1KCNH2CDK4CDKL1 | |
| SCHEMBL1448420 | 0.86 | CDK2 (0.73) | CDK2CDK1KCNH2CDK4CDKL1 | |
| SCHEMBL12861893 | 0.86 | CDK2 (0.73) | CDK2CDK1KCNH2 | |
| Hydrochloric Acid SCHEMBL1156075 | 0.85 | CDK2 (0.72) | CDK2CDK1KCNH2 | |
| SCHEMBL1447917 | 0.85 | CDK2 (0.71) | CDK2CDK1KCNH2CDK4CDKL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2301928-A1 | Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders | AstraZeneca AB (SE) | 2011-03-30 | — | — | EP | disclosed |
| US-20080280906-A1 | Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280906-A1 | Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders | CCNI, MKI67, TYMP | CDK2 13/4885CDK1 35/4885KCNH2 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.